Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efpeglenatide Monthly Dose Finding in T2DM
NCT02081118Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Feb 2014
- Primary completion
- Mar 2015
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efpeglenatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Change in baseline in glycosylated haemoglobin at 16 weeks. Started Feb 2014; status: completed.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02081118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02081118.